156 related articles for article (PubMed ID: 36029150)
1. Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.
Sharma S; Pepin X; Burri H; Zheng L; Kuptsova-Clarkson N; de Jong A; Yu T; MacArthur HL; Majewski M; Byrd JC; Furman RR; Ware JA; Mann J; Ramies D; Munugalavadla V; Sheridan L; Tomkinson H
Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1294-1307. PubMed ID: 36029150
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.
Sharma S; Pepin X; Cheung J; Zheng L; Wei H; Townsley D; Han D; Majewski M; Ware JA; Mann J; Munugalavadla V; Sheridan L; Patel P; Gupta A; Tomkinson H
Br J Clin Pharmacol; 2022 Oct; 88(10):4573-4584. PubMed ID: 35466438
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study.
Shaik N; Hee B; Wei H; LaBadie RR
Cancer Chemother Pharmacol; 2019 Mar; 83(3):463-472. PubMed ID: 30536154
[TBL] [Abstract][Full Text] [Related]
4. Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices.
Pepin XJH; Moir AJ; Mann JC; Sanderson NJ; Barker R; Meehan E; Plumb AP; Bailey GR; Murphy DS; Krejsa CM; Andrew MA; Ingallinera TG; Slatter JG
Eur J Pharm Biopharm; 2019 Sep; 142():435-448. PubMed ID: 31306750
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects.
Harada A; Ikushima I; Haranaka M; Yanagihara A; Nakayama D
Am J Cardiovasc Drugs; 2020 Jun; 20(3):249-258. PubMed ID: 31667735
[TBL] [Abstract][Full Text] [Related]
6. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
7. Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An
Piscitelli J; Hens B; Tomaszewska I; Wollenberg L; Litwiler K; McAllister M; Reddy M
Mol Pharm; 2023 May; 20(5):2589-2599. PubMed ID: 37037186
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans.
Podoll T; Pearson PG; Evarts J; Ingallinera T; Bibikova E; Sun H; Gohdes M; Cardinal K; Sanghvi M; Slatter JG
Drug Metab Dispos; 2019 Feb; 47(2):145-154. PubMed ID: 30442651
[TBL] [Abstract][Full Text] [Related]
9. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Byrd JC; Harrington B; O'Brien S; Jones JA; Schuh A; Devereux S; Chaves J; Wierda WG; Awan FT; Brown JR; Hillmen P; Stephens DM; Ghia P; Barrientos JC; Pagel JM; Woyach J; Johnson D; Huang J; Wang X; Kaptein A; Lannutti BJ; Covey T; Fardis M; McGreivy J; Hamdy A; Rothbaum W; Izumi R; Diacovo TG; Johnson AJ; Furman RR
N Engl J Med; 2016 Jan; 374(4):323-32. PubMed ID: 26641137
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.
Edlund H; Lee SK; Andrew MA; Slatter JG; Aksenov S; Al-Huniti N
Clin Pharmacokinet; 2019 May; 58(5):659-672. PubMed ID: 30556110
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
[TBL] [Abstract][Full Text] [Related]
12. Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies.
Edlund H; Buil-Bruna N; Vishwanathan K; Wei H; Raman R; de Kock M; He Z; Liu H; Baek M; Ware J; Patel P; Tomkinson H; Sharma S
Br J Clin Pharmacol; 2022 May; 88(5):2284-2296. PubMed ID: 34532877
[TBL] [Abstract][Full Text] [Related]
13. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Wolska-Washer A; Robak T
Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194
[TBL] [Abstract][Full Text] [Related]
14. Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors .
Podoll T; Pearson PG; Kaptein A; Evarts J; de Bruin G; Emmelot-van Hoek M; de Jong A; van Lith B; Sun H; Byard S; Fretland A; Hoogenboom N; Barf T; Slatter JG
J Pharmacol Exp Ther; 2023 Jan; 384(1):173-186. PubMed ID: 36310034
[TBL] [Abstract][Full Text] [Related]
15. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
Khan Y; O'Brien S
Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
[TBL] [Abstract][Full Text] [Related]
16. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
Miao Y; Xu W; Li J
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396
[TBL] [Abstract][Full Text] [Related]
17. Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Ghia P; Dlugosz-Danecka M; Scarfò L; Jurczak W
Leuk Lymphoma; 2021 May; 62(5):1066-1076. PubMed ID: 33427570
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Morphine Sulfate Orodispersible Tablets and Bioequivalence with Immediate-Release Oral Morphine Sulfate Formulations in Healthy Adult Subjects Under Fasting Conditions: Single-Dose Comparative Bioavailability Studies.
Atrux-Tallau N; Naimi Z; Jaudinot EO
Clin Drug Investig; 2022 Dec; 42(12):1101-1112. PubMed ID: 36331670
[TBL] [Abstract][Full Text] [Related]
20. The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
Anderson K; Zheng H; Kotecha M; Cuvin J; Scott B; Sharma S; Qin AR; Namour F; Xin Y
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):585-594. PubMed ID: 30768860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
